Bausch Health Companies | VRX - Gross Profit On Sales


Bausch Health Companies reported $2B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Amgen USD 6.89B 415M Dec/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Bausch Health Companies USD 2B 67M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Danaher USD 3.59B 375M Mar/2026
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Zoetis USD 1.62B 20M Mar/2026